ReviewAmerican journal of kidney diseases : the official journal of the National Kidney Foundation2025
Autosomal Dominant Polycystic Kidney Disease: Core Curriculum 2025.
Review in American journal of kidney diseases : the official journal of the National Kidney Foundation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Metformin in non-diabetic patients with autosomal dominant polycystic kidney disease: a systematic review and meta-analysis of randomized controlled trials.BMC nephrology · 2025Pooled it
- A rapid automated segmentation method for total kidney volume measurement on unenhanced computed tomography in autosomal dominant polycystic kidney disease.Abdominal radiology (New York) · 2026Article
- Increased risk of incident and recurrent urinary tract infection in autosomal dominant polycystic kidney disease: a contemporary propensity score-matched cohort study.Internal and emergency medicine · 2026Article
- Polyphenols and ADPKD: A Further Aid from Nature?Life (Basel, Switzerland) · 2026Review
- Exploring multiple drug actions of a CaNaunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Macroscopic hematuria in children with autosomal dominant polycystic kidney disease - report from four European tertiary centers.European journal of pediatrics · 2026Article
- Endocannabinoid System-Related Inflammation and Progression of Autosomal Dominant Polycystic Kidney Disease.International journal of molecular sciences · 2026Article
- Advances in the Treatment of Autosomal Dominant Polycystic Kidney Disease and Novel Therapeutic Targets.Current issues in molecular biology · 2026Review
- Association of Kidney Volume With Patient-Reported Outcomes in ADPKD.Kidney international reports · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Autosomal dominant polycystic kidney disease (ADPKD) is the most common genetic cause of kidney failure. Scientific advances have improved the approach to diagnosis, prognosis, and management of renal and extrarenal manifestations. The combination of total kidney volume, kidney function, and the genetic mutation (if known), predicts risk for progression to kidney failure, thereby identifying patients in whom disease modifying therapy is recommended. Currently there is one therapy approved by the US Food and Drug Administration (FDA) for slowing ADPKD progression, the V2 receptor antagonist, tolvaptan. Other therapies are under active investigation for ADPKD. This Core Curriculum discusses diagnosis and management of the renal and extrarenal manifestations seen in ADPKD including acute and chronic pain and cyst infection and polycystic liver disease and intracranial aneurysm. Management of hypertension and women's health and pregnancy management in ADPKD are covered. This review was aligned with the findings of the recently published Kidney Disease Improving Global Outcomes (KDIGO) clinical practice guideline for the Evaluation, Management, and Treatment of ADPKD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.